Effects of candesartan cilexetil on glucose homeostasis

被引:0
作者
Trenkwalder P. [1 ]
机构
[1] Medicine Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich, D-82319 Starnberg
关键词
Angiotensin receptor blockers; Candesartan cilexetil; Diabetes mellitus; Glucose homeostasis; Serum lipids;
D O I
10.1007/s003950050241
中图分类号
学科分类号
摘要
In a multicenter, randomized, double-blind, placebo-controlled clinical trial the effects of candesartan cilexetil (cand.cil.), a novel angiotensin II antagonist selective for the AT1 receptor with long-lasting antihypertensive activity, on glucose homeostasis - and the serum lipid profile - were assessed in patients with mild hypertension and stable type II diabetes mellitus. A total of 161 men and women, 30-75 years old, with mild hypertension (sitting diastolic blood pressure 90-100 mmHg) and type II diabetes (HbA1c 5.5-9.0 %), both measured after a 4-week placebo run-in period, were randomized to double-blind treatment with cand.cil. 8 mg o.i.d. (n = 83) or placebo (n = 78). Dose was increased to 16 mg o.i.d., if diastolic blood pressure remained ≥90 mmHg. At randomization and after 12 weeks of treatment HbA1c (primary effect variable), blood glucose and the serum lipid profile (including total cholesterol, HDL and LDL cholesterol, triglycerides) were assessed. The statistical analysis of the differences between treatments was based on changes from randomization to the end of the study. Cand.cil. had no significant effect on HbA1c, blood glucose, and serum lipids compared to placebo. The median HbA1c both at baseline and after 12 weeks was 7.1 % in patients on cand.cil., and 7.2 % and 7.1 % in patients on placebo. The 95 % confidence interval for the median difference in change between the groups was narrow (-0.25; 0.16), including zero, which excluded any clinically important difference. The same held true for blood glucose (-1.10; 0.20), total cholesterol (- 0.40; 0.20), and the other lipid parameters. More than 60 % of the patients reached a diastolic blood pressure < 90 mmHg; adverse events and withdrawals were similar in both groups. Thus, in patients with mild hypertension and type II diabetes, cand.cil. 8 to 16 mg o.i.d. for 12 weeks does not affect glucose homeostasis respectively serum lipids. Blood pressure was controlled in most patients and cand.cil. was well tolerated. © Steinkopff Verlag 1998.
引用
收藏
页码:140 / 144
页数:4
相关论文
共 19 条
[1]  
Chow L., De Gasparo M., Levens N., Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors, Europ J Pharmacol, 282, pp. 77-86, (1995)
[2]  
Delacretaz E., Nussberger J., Biollaz J., Waeber B., Brunner H.R., Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers, Hypertension, 25, pp. 14-21, (1995)
[3]  
Ferrari P., Rosman J., Weidmann P., Antihypertensive agents, serum lipoproteins and glucose metabolism, Am J Cardiol, 67, (1991)
[4]  
Goa K.L., Wagstaff A.J., Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension, Drugs, 51, pp. 820-845, (1996)
[5]  
Herings R.M., De Boer A., Stricker B.H., Leufkens H.G., Porsius A., Hypoglyeaemia associated with use of inhibitors of angiotensin converting enzyme, Lancet, 345, pp. 1195-1198, (1995)
[6]  
Iimura O., Shimamoto K., Matsuda K., Effects of angiotensin receptor antagonists and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives, Am J Hypertens, 8, pp. 353-357, (1995)
[7]  
The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V), Arch Intern Med, 153, pp. 154-183, (1993)
[8]  
Kannel W.B., Potency of vascular risk factors as the basis for antihypertensive therapy, European Heart Journal, 13, SUPPL. G, pp. 34-42, (1992)
[9]  
Kaplan N.M., Combination therapy for systemic hypertension, Am J Cardiol, 76, pp. 595-597, (1995)
[10]  
Laakso M., Karjalainen L., Lempiainen-Kuosa P., Effects of losartan on insulin sensitivity in hypertensive subjects, Hypertension, 28, 3, pp. 392-396, (1996)